安络化纤丸联合恩替卡韦治疗乙肝肝硬化的效果及对肝功能的影响

Abstract
Figure/Table
References (23)
Related Citation (11)

Download: PDF (439 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore clinical effect of Anluohuaxian Pills combined with Entecavir in the treatment of hepatitis B cirrhosis. Methods Sixty-eight patients with hepatitis B cirrhosis admitted to Hebei Traditional Chinese Medicine and Liver Disease Hospital from June 2017 to June 2018 were selected and divided into two groups according to random number table method, 34 cases in each group. Control group received Entecavir treatment, observation group received Anluohuaxian Pills combined with Entecavir treatment, the course of treatment lasted for one year. The negative conversion rate of HBV-DNA and HBeAg, Child-Pugh score and liver function index, serum liver fibrosis index, liver spleen imaging index and adverse reactions were compared between two groups. Results The negative conversion rates of HBV-DNA and HBeAg in observation group after treatment were higher than those in control group (P < 0.05). After treatment, Child-Pugh score, albumin and total bilirubin levels of observation group were lower than those of control group, and alanine aminotransferase level of observation group was higher than that of control group, the differences were statistically significant (P < 0.05). After treatment, the serum levels of hyaluronic acid, human laminin and procollagen type Ⅲ in observation group were lower than those in control group (P < 0.05). The diameter of portal vein trunk, the length of spleen and the proportion of splenic vein in observation group were significantly higher than those in control group (P < 0.05). No adverse reactions occurred during the treatment. Conclusion Anluohuaxian Pills combined with Entecavir in the treatment of hepatitis B cirrhosis has exact effect, it can significantly improve the liver function of patients, and relieve the deterioration trend of liver fiber related indicators, it is a kind of therapy worthy of promotion.

Key words： Anluohuaxian Pills Entecavir Hepatitis B cirrhosis Child-Pugh score Liver function index Liver fibrosis index Liver and spleen imaging

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Zhaohui1 ZHANG Xiaolong2 GUO Yanqing3 WANG Xiaoling3 SHEN Lixian3 KANG Yanyan1 FANG Chongchong1 QI Xinci1

Cite this article:

LI Zhaohui1 ZHANG Xiaolong2 GUO Yanqing3 WANG Xiaoling3 SHEN Lixian3 KANG Yanyan1 FANG Chongchong1 QI Xinci1. Effect of Anluohuaxian Pills combined with Entecavir in the treatment of hepatitis B cirrhosis and its influence on liver function[J]. 中国医药导报, 2020, 17(28): 151-154.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I28/151

[1] 杨冬冬，祐红瑞，李雅.安络化纤丸联合恩替卡韦治疗乙肝肝硬化的临床价值分析[J].四川解剖学杂志，2019，27（3）：62-63.
[2] 金艳杰.安络化纤丸联合恩替卡韦治疗乙肝肝硬化的临床疗效研究[J].中西医结合研究，2018，10（5）：229-232.
[3] 海志丹.恩替卡韦分散片联合安络化纤丸治疗乙肝肝硬化的临床疗效观察[J].世界最新医学信息文摘：连续型电子期刊，2019，19（97）：184-186.
[4] 李彩虹，连琳琳，高菲，等.安络化纤丸联合恩替卡韦对老年活动性代偿期乙肝肝硬化患者肝功能、肝纤维化及肝脾影像学指标的影响[J].实用医院临床杂志，2018， 15（4）：232-234.
[5] 窦永青，郝彦琴，李红，等.恩替卡韦分散片与安络化纤丸联合治疗对乙肝肝硬化预后的影响[J].临床医药实践，2017，26（12）：885-888.
[6] 何洪，钟伟章，雷燕.恩替卡韦对初期治疗不同时期乙肝肝硬化患者抗病毒的疗效[J].中国现代药物应用，2018， 12（11）：97-99.
[7] 李静.恩替卡韦联合安络化纤丸治疗乙肝后肝硬化失代偿期106例近期疗效观察[J].医药论坛杂志，2017，38（2）：154-155.
[8] 温智稀，王振常，郑景辉，等.恩替卡韦合安络化纤丸治疗乙肝肝硬化Meta分析[J].光明中医，2016，31（12）：1722-1726.
[9] 王辉.肝硬化患者凝血四项、D-二聚体水平及AT-Ⅲ的表达及临床意义[J].中国现代医生，2019，57（8）：115-117.
[10] 陈甜，吴艺锋，张烨琼.外周血Th细胞水平在肝炎肝硬化肝癌中的检测价值[J].河北医学，2019，25（3）：542-548.
[11] 段红岩.微生态制剂联合抗病毒治疗对乙肝肝硬化患者免疫功能及肝纤维化指标的影响[J].河北医学，2019， 25（11）：1861-1865.
[12] 贾春辉，刘伯强，李旭丽，等.安络化纤丸联合恩替卡韦对慢性HBV感染者病毒复制及肝纤维化指标、Th1/Th2细胞因子影响[J].辽宁中医药大学学报，2017，19（12）：146-149.
[13] 罗金保.安络化纤丸对乙肝肝硬化的疗效评价[J].中国实用医药，2016，11（28）：199-200.
[14] 刘崧，柯晓芳，安良敏，等.乙型肝炎肝硬化代偿期患者应用恩替卡韦抗病毒的临床疗效分析[J].吉林医学，2017，38（5）：902-904.
[15] 热沙来提·牙合甫，丽娜，杨家民.恩替卡韦对安络化纤丸治疗乙肝肝硬化组织学变化的影响[J].新疆医学，2013，43（8）：61-63.
[16] 杨俊.安络化纤丸治疗乙肝肝硬化患者的疗效观察[J].医药论坛杂志，2015，36（3）：143-144.
[17] 张薇薇，袁学华，谭华炳，等.恩替卡韦联合安络化纤丸治疗代偿期乙肝后肝硬化临床观察[J].湖北中医杂志，2011，33（3）：13-14.
[18] 李静.恩替卡韦联合安络化纤丸治疗乙肝后肝硬化失代偿期48例近期疗效观察[J].医药论坛杂志，2011，32（16）：154-156.
[19] 秦华.替诺福韦酯联合安络化纤丸对乙肝肝硬化失代偿期患者肝纤维化程度的影响[J].甘肃医药，2019，38（7）：609-611.
[20] 赵艳.拉米夫定联合安络化纤丸治疗乙肝肝硬化临床观察[J].中国医药导报，2016，13（6）：170-173.
[21] 周家杰，刘伟玲，周小惠.安络化纤丸联合阿德福韦、拉米夫定治疗乙肝肝硬化患者的效果以及对肝组织学变化的影响[J].内科，2017，12（5）：667-669.
[22] 刘崧，安良敏，余素琼，等.用Fibroscan对安络化纤丸治疗乙肝肝硬化疗效评定[J].海峡药学，2016（7）：169-170.
[23] 夏云芳，陈敬国，夏荣华.安络化纤丸对乙肝后肝硬化肝纤四项的影响[J].内蒙古中医药，2017，36（6）：10.